A delay differential model for pandemic influenza with antiviral treatment.
Identifieur interne : 001858 ( PubMed/Checkpoint ); précédent : 001857; suivant : 001859A delay differential model for pandemic influenza with antiviral treatment.
Auteurs : Murray E. Alexander ; Seyed M. Moghadas ; Gergely Röst ; Jianhong WuSource :
- Bulletin of mathematical biology [ 0092-8240 ] ; 2008.
Descripteurs français
- KwdFr :
- Acceptation des soins par le patient, Antiviraux (usage thérapeutique), Attitude envers la santé, Contrôle des maladies contagieuses (), Diagnostic précoce, Facteurs temps, Flambées de maladies (), Grippe humaine (), Grippe humaine (épidémiologie), Humains, Incidence, Modèles logistiques, Orthomyxoviridae (pathogénicité), Prise en charge de la maladie, Transmission de maladie infectieuse ().
- MESH :
- pathogénicité : Orthomyxoviridae.
- usage thérapeutique : Antiviraux.
- épidémiologie : Grippe humaine.
- Acceptation des soins par le patient, Attitude envers la santé, Contrôle des maladies contagieuses, Diagnostic précoce, Facteurs temps, Flambées de maladies, Grippe humaine, Humains, Incidence, Modèles logistiques, Prise en charge de la maladie, Transmission de maladie infectieuse.
English descriptors
- KwdEn :
- Antiviral Agents (therapeutic use), Attitude to Health, Communicable Disease Control (statistics & numerical data), Disease Management, Disease Outbreaks (statistics & numerical data), Disease Transmission, Infectious (prevention & control), Disease Transmission, Infectious (statistics & numerical data), Early Diagnosis, Humans, Incidence, Influenza, Human (epidemiology), Influenza, Human (therapy), Logistic Models, Orthomyxoviridae (pathogenicity), Patient Acceptance of Health Care, Time Factors.
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- epidemiology : Influenza, Human.
- pathogenicity : Orthomyxoviridae.
- prevention & control : Disease Transmission, Infectious.
- statistics & numerical data : Communicable Disease Control, Disease Outbreaks, Disease Transmission, Infectious.
- therapy : Influenza, Human.
- Attitude to Health, Disease Management, Early Diagnosis, Humans, Incidence, Logistic Models, Patient Acceptance of Health Care, Time Factors.
Abstract
The use of antiviral drugs has been recognized as the primary public health strategy for mitigating the severity of a new influenza pandemic strain. However, the success of this strategy requires the prompt onset of therapy within 48 hours of the appearance of clinical symptoms. This requirement may be captured by a compartmental model that monitors the density of infected individuals in terms of the time elapsed since the onset of symptoms. We show that such a model can be expressed by a system of delay differential equations with both discrete and distributed delays. The model is analyzed to derive the criterion for disease control based on two critical factors: (i) the profile of treatment rate; and (ii) the level of treatment as a function of time lag in commencing therapy. Numerical results are also obtained to illustrate the feasible region of disease control. Our findings show that due to uncertainty in the attack rate of a pandemic strain, initiating therapy immediately upon diagnosis can significantly increase the likelihood of disease control and substantially reduce the required community-level of treatment. This suggests that reliable diagnostic methods for influenza cases should be rapidly implemented within an antiviral treatment strategy.
DOI: 10.1007/s11538-007-9257-2
PubMed: 17701376
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17701376Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">A delay differential model for pandemic influenza with antiviral treatment.</title><author><name sortKey="Alexander, Murray E" sort="Alexander, Murray E" uniqKey="Alexander M" first="Murray E" last="Alexander">Murray E. Alexander</name><affiliation><nlm:affiliation>Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, R3B 1Y6.</nlm:affiliation><wicri:noCountry code="subField">R3B 1Y6</wicri:noCountry></affiliation></author><author><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name></author><author><name sortKey="Rost, Gergely" sort="Rost, Gergely" uniqKey="Rost G" first="Gergely" last="Röst">Gergely Röst</name></author><author><name sortKey="Wu, Jianhong" sort="Wu, Jianhong" uniqKey="Wu J" first="Jianhong" last="Wu">Jianhong Wu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:17701376</idno><idno type="pmid">17701376</idno><idno type="doi">10.1007/s11538-007-9257-2</idno><idno type="wicri:Area/PubMed/Corpus">001A92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A92</idno><idno type="wicri:Area/PubMed/Curation">001A92</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A92</idno><idno type="wicri:Area/PubMed/Checkpoint">001858</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001858</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">A delay differential model for pandemic influenza with antiviral treatment.</title><author><name sortKey="Alexander, Murray E" sort="Alexander, Murray E" uniqKey="Alexander M" first="Murray E" last="Alexander">Murray E. Alexander</name><affiliation><nlm:affiliation>Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, R3B 1Y6.</nlm:affiliation><wicri:noCountry code="subField">R3B 1Y6</wicri:noCountry></affiliation></author><author><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name></author><author><name sortKey="Rost, Gergely" sort="Rost, Gergely" uniqKey="Rost G" first="Gergely" last="Röst">Gergely Röst</name></author><author><name sortKey="Wu, Jianhong" sort="Wu, Jianhong" uniqKey="Wu J" first="Jianhong" last="Wu">Jianhong Wu</name></author></analytic><series><title level="j">Bulletin of mathematical biology</title><idno type="ISSN">0092-8240</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Attitude to Health</term><term>Communicable Disease Control (statistics & numerical data)</term><term>Disease Management</term><term>Disease Outbreaks (statistics & numerical data)</term><term>Disease Transmission, Infectious (prevention & control)</term><term>Disease Transmission, Infectious (statistics & numerical data)</term><term>Early Diagnosis</term><term>Humans</term><term>Incidence</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (therapy)</term><term>Logistic Models</term><term>Orthomyxoviridae (pathogenicity)</term><term>Patient Acceptance of Health Care</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Antiviraux (usage thérapeutique)</term><term>Attitude envers la santé</term><term>Contrôle des maladies contagieuses ()</term><term>Diagnostic précoce</term><term>Facteurs temps</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (épidémiologie)</term><term>Humains</term><term>Incidence</term><term>Modèles logistiques</term><term>Orthomyxoviridae (pathogénicité)</term><term>Prise en charge de la maladie</term><term>Transmission de maladie infectieuse ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Communicable Disease Control</term><term>Disease Outbreaks</term><term>Disease Transmission, Infectious</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Attitude to Health</term><term>Disease Management</term><term>Early Diagnosis</term><term>Humans</term><term>Incidence</term><term>Logistic Models</term><term>Patient Acceptance of Health Care</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acceptation des soins par le patient</term><term>Attitude envers la santé</term><term>Contrôle des maladies contagieuses</term><term>Diagnostic précoce</term><term>Facteurs temps</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Incidence</term><term>Modèles logistiques</term><term>Prise en charge de la maladie</term><term>Transmission de maladie infectieuse</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The use of antiviral drugs has been recognized as the primary public health strategy for mitigating the severity of a new influenza pandemic strain. However, the success of this strategy requires the prompt onset of therapy within 48 hours of the appearance of clinical symptoms. This requirement may be captured by a compartmental model that monitors the density of infected individuals in terms of the time elapsed since the onset of symptoms. We show that such a model can be expressed by a system of delay differential equations with both discrete and distributed delays. The model is analyzed to derive the criterion for disease control based on two critical factors: (i) the profile of treatment rate; and (ii) the level of treatment as a function of time lag in commencing therapy. Numerical results are also obtained to illustrate the feasible region of disease control. Our findings show that due to uncertainty in the attack rate of a pandemic strain, initiating therapy immediately upon diagnosis can significantly increase the likelihood of disease control and substantially reduce the required community-level of treatment. This suggests that reliable diagnostic methods for influenza cases should be rapidly implemented within an antiviral treatment strategy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17701376</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0092-8240</ISSN><JournalIssue CitedMedium="Print"><Volume>70</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bulletin of mathematical biology</Title><ISOAbbreviation>Bull. Math. Biol.</ISOAbbreviation></Journal><ArticleTitle>A delay differential model for pandemic influenza with antiviral treatment.</ArticleTitle><Pagination><MedlinePgn>382-97</MedlinePgn></Pagination><Abstract><AbstractText>The use of antiviral drugs has been recognized as the primary public health strategy for mitigating the severity of a new influenza pandemic strain. However, the success of this strategy requires the prompt onset of therapy within 48 hours of the appearance of clinical symptoms. This requirement may be captured by a compartmental model that monitors the density of infected individuals in terms of the time elapsed since the onset of symptoms. We show that such a model can be expressed by a system of delay differential equations with both discrete and distributed delays. The model is analyzed to derive the criterion for disease control based on two critical factors: (i) the profile of treatment rate; and (ii) the level of treatment as a function of time lag in commencing therapy. Numerical results are also obtained to illustrate the feasible region of disease control. Our findings show that due to uncertainty in the attack rate of a pandemic strain, initiating therapy immediately upon diagnosis can significantly increase the likelihood of disease control and substantially reduce the required community-level of treatment. This suggests that reliable diagnostic methods for influenza cases should be rapidly implemented within an antiviral treatment strategy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Murray E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, R3B 1Y6.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghadas</LastName><ForeName>Seyed M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Röst</LastName><ForeName>Gergely</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jianhong</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>08</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Bull Math Biol</MedlineTA><NlmUniqueID>0401404</NlmUniqueID><ISSNLinking>0092-8240</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003140" MajorTopicYN="N">Communicable Disease Control</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="N">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018562" MajorTopicYN="N">Disease Transmission, Infectious</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>01</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>06</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17701376</ArticleId><ArticleId IdType="doi">10.1007/s11538-007-9257-2</ArticleId><ArticleId IdType="pmc">PMC7088798</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2006 Jan 28;367(9507):303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16443037</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2004 Apr 1;159(7):623-33</Citation><ArticleIdList><ArticleId IdType="pubmed">15033640</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Apr;177(4):863-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9534957</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):15-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16494711</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2003 May 1;21(16):1801-3</Citation><ArticleIdList><ArticleId IdType="pubmed">12686098</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2003 Apr;51(4):977-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12654752</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Jul 27;442(7101):448-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16642006</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Sep 8;437(7056):209-14</Citation><ArticleIdList><ArticleId IdType="pubmed">16079797</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2006 Aug;80(15):7590-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16840338</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2001 Aug;51(2):81-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11431034</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Biol Sci. 2004 Nov 7;271(1554):2223-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15539347</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Sep;11(9):1355-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16229762</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2006 Jan;12(1):81-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16494722</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Aug 12;309(5737):1083-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16079251</ArticleId></ArticleIdList></Reference><Reference><Citation>J R Soc Interface. 2006 Jun 22;3(8):453-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16849273</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5935-40</Citation><ArticleIdList><ArticleId IdType="pubmed">16585506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Alexander, Murray E" sort="Alexander, Murray E" uniqKey="Alexander M" first="Murray E" last="Alexander">Murray E. Alexander</name><name sortKey="Moghadas, Seyed M" sort="Moghadas, Seyed M" uniqKey="Moghadas S" first="Seyed M" last="Moghadas">Seyed M. Moghadas</name><name sortKey="Rost, Gergely" sort="Rost, Gergely" uniqKey="Rost G" first="Gergely" last="Röst">Gergely Röst</name><name sortKey="Wu, Jianhong" sort="Wu, Jianhong" uniqKey="Wu J" first="Jianhong" last="Wu">Jianhong Wu</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001858 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001858 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17701376
|texte= A delay differential model for pandemic influenza with antiviral treatment.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17701376" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |